[Low-molecular transfer factor and its use in the treatment of amyotrophic lateral sclerosis].
A low-molecular leukocyte dialysate, suppressor transfer factor (STF), exerting a stimulating effect on CD8 subpopulations in man, was administered to 17 patients with amyotrophic lateral sclerosis (ALS). Following three s.c. injections of STF, activation of CD8 subpopulations was noted in 11 patients while a decrease in CD4 in seven. Progression of the disease was found to slow in nine outpatients administered STF injections at an interval of 3-4 weeks. No therapeutic effect was seen in four patients in whom STF injection failed to show stimulating activity on lymphocyte subpopulations. Remission of the stimulating effect of STF occurs within four weeks. No side effects were seen in any of the patients treated. The effect of STF on immune reactivity and on the clinical course of ALS supports the hypothesis of autoimmune character of the disease.
Nevsímal
O
O
Neurologická klinika 1. Lék. Fak. UK, Praha.
Pekárek
J
J
Koubek
K
K
Cech
K
K
Sonková
Z
Z
D000328:Adult; D000690:Amyotrophic Lateral Sclerosis / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D014165:Transfer Factor / Q000627:therapeutic use*
D014165:Transfer Factor
Nízkomolekulární transfer faktor a jeho vyuzití pri lécení amyotrofické laterální sklerózy.